Meeting
2017 ASCO Annual Meeting
Effects of temozolomide and bevacizumab in relapsed patients with heavily pretreated uterine leiomyosarcoma.
Authors
Hiroko Matsuura
National Defense Medical College, Tokorozawa, Japan
Hiroko Matsuura , Sayaka Ikeda , Kazuya Kudoh , Naoki Sasaki , Masashi Takano , Tomoko Goto , Ryoko Kikuchi , Tsunekazu Kita , Masaru Sakamoto , Daisuke Aoki , Nobuyuki Susumu , Hiroko Kouta , Yoshihiro Kikuchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11056)
DOI
10.1200/JCO.2017.35.15_suppl.11056
Abstract #
11056
Poster Bd #
379
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma.
First Author: Sayaka Ikeda
Poster
2014 ASCO Annual Meeting
Effects of temozolomide and bevacizumab in patients with pretreated relapsed uterine leiomyosarcoma.
First Author: Naoki Sasaki
First Author: Lucas Moreno
Poster
2015 ASCO Annual Meeting
GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.
First Author: Roberta Ruda